Auspex adds weight as it raises $25m to progress deuterium-modified pipeline
This article was originally published in Scrip
Executive Summary
Auspex Pharmaceuticals has raised $25 million in a Series D venture financing round to conduct a pivotal Phase III clinical trial for SD-809, a version of the drug Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease, in which the San Diego-based company believes it has improved pharmacokinetic properties by substituting certain hydrogen atoms with the "heavy" hydrogen isotope deuterium.